Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Bloomberg's Wednesday report promised MFN agreements with midsize biotechs as soon as Monday. Monday delivered the agreements. Now read the label. Of nine signatories, one is a US biotech, and it sells a single approved drug in a disease where the comparator countries already set the price. The rest are foreign midcaps with US plants and mature portfolios, and the largest of them, Teva, issued its own release calling the whole thing an intent to reach agreement. The companies the report was about, the alliance that formed in February to fight this policy, are absent to a name.

That is this week's rule applied to a policy event instead of a drug. The headline said midsize biotech capitulation. The primary documents say the administration found nine companies for whom Medicaid alignment costs little and a Section 232 exemption is worth a lot, and counted Teva, which by its own account has not finalized, to reach nine. For Alnylam and BioMarin holders nothing was resolved Monday; the tariff threat and the September 30 GENEROUS deadline still hang, and the pressure now has a template. Monday's tally for the week: seven US traded sponsors delivered a promised event, one closed higher, and it was the one that published no numbers. 👉 Read Full Analysis

🏛️ Policy

Nine companies joined the MFN program, and the ones the story was about did not. BBIO | TEVA | ONC | ALNY | BMRN

The White House fact sheet lists Alcon, Astellas, BeOne, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB, claims 26 manufacturers covering 89% of the branded market, and totals a $19.6 billion US manufacturing pledge without itemizing it. The company releases are where the shape shows. BridgeBio puts Attruby into Medicaid through the GENEROUS Model and says it does not expect to face future pricing mandates. BeOne ties a Section 232 exemption to $300 million more at its New Jersey plant. Teva describes active discussions and terms that apply when finalized. Fierce Pharma reports that none of the Midsized Biotech Alliance's original members appear, and Alnylam and BioMarin, the two names Bloomberg's report put in frame, are not on the list; STAT notes the Medicare impact has not been released. Round one took seven months to get from Pfizer to Regeneron. Round two shows what the administration could sign in four: foreign parents, existing US capacity, and one American biotech whose reference prices were already fixed abroad. Signatory closes, per exchange data: BBIO flat, TEVA down 1.1%, ONC down 1.9%, UCB down 1.0%.

💰 Deals

Lilly paid up to $2.875 billion for a Phase 1 antibody degrader and did not say how much is firm. LLY

Lilly will acquire Merida Biosciences for up to $2.875 billion in cash, an upfront payment plus milestones that the release does not separate, with closing expected in the fourth quarter. The asset is MER511, a biologic that selectively degrades the thyroid stimulating autoantibodies behind Graves' disease and thyroid eye disease, in a Phase 1 that began in December per Fierce Biotech; Lilly says early data showed robust antibody reductions and a favorable initial safety profile, and gives no numbers. A preclinical IgE program for food allergy and asthma and early kidney work come along. Merida left stealth in 2025 with $121 million from Third Rock, per Fierce. On the binary ledger this is column six entry eleven, and like Lilly's Amplitude deal it lands in the undisclosed bucket, which is its own kind of disclosure. LLY closed down 1.5%, market data, no cause assigned. The Pro brief works out what the missing number can and cannot be.

🧬 Rare Disease

BioMarin turned a five jurisdiction patent fight into a 20% royalty through 2030. BMRN | ASND

Under a binding term sheet, Ascendis will pay BioMarin 20% of US net sales of Yuviwel, retroactive to first commercial sale, and 18% in the EU, Brazil and South Korea, through May 20, 2030, covering every current and potential indication including hypochondroplasia, in exchange for dismissing the ITC case and litigation in California, Brazil, Denmark, Germany and South Korea. No upfront was disclosed. Ascendis reiterated its cash flow and 2030 revenue guidance, which tells you it had budgeted for this. Per Fierce, Yuviwel booked €8 million in its first partial quarter and 90% of BioMarin's US patients were still on Voxzogo in July, and Jefferies sees $720 million of combined royalties by 2030. The market read it as a win for both: BMRN closed up 0.9%, ASND up 6.1%. Note who BioMarin is this week: an alliance member with a growing royalty stream on a competitor's drug, and no MFN agreement.

❤️ Cardiology

Arrowhead's full data changed nothing that was in the topline, and the stock fell anyway. ARWR | IONS

The SHASTA-3 and SHASTA-4 presentation at ESC put confidence intervals on numbers the market has held since July 22: median triglycerides down 79% and 81% at month 12, pooled acute pancreatitis events down 78% (rate ratio 0.22, p=0.008), a number needed to treat of 24 in the broad population and 3 in the prior pancreatitis subgroup, per Arrowhead's release. What was new: 757 patients, serious adverse events 8.3% versus 10% on placebo, no anaphylaxis, no Hy's law, three deaths on drug attributed to preexisting disease, and worsening glycemic control in 14.3% versus 8.7%. Stifel called it arguably best in class and BMO favored Ionis's Tryngolza on the diabetes question, per BioSpace. ARWR closed down 3.0% on top of Friday's 4.2%. That is the third time in four sessions a congress presentation of already disclosed numbers has repriced the sponsor lower, after Cytokinetics and Ionis. The filing comes before year end with a priority review voucher attached, and the glycemic line is now the label question.

🕳️ The Tally

The one delivered catalyst that closed higher was the one with no numbers. JAZZ

Jazz said the Ziihera plus chemotherapy arm of HERIZON-GEA-01, the doublet the FDA approved last week for IHC 3+ disease, reached a statistically significant overall survival benefit over trastuzumab plus chemotherapy at the second interim, with the hazard ratio improved from the first look, and disclosed no hazard ratio, median or p value ahead of a fourth quarter meeting. JAZZ closed up 2.5%. On the same day PharmaEssentia's Besremi was approved in essential thrombocythemia one calendar day after a Sunday target, with a release that says superior durable responses and reduced thromboembolic events and prints no figures either; the sponsor trades in Taiwan, so it has no US close to log. Monday's line for the week's tally: MFN round delivered, four US signatories flat or lower; Arrowhead delivered, lower; AstraZeneca's Luminara Phase 2 delivered, AZN down 0.4%; Jazz delivered, higher. Seven sponsors, one up. Friday prints the full ratio.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

Nine signatures and a fact sheet made a headline; the company releases made a label, and the label was smaller. Seven delivered events, one sponsor up, and the tally runs through Friday. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →